Skip to content

Clinical trials

Completed Urinary Tract Infections trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Urinary Tract Infections Status: Completed Clear all

390 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20016
20022
20039
200410
200512
200610
200712
200811
200914
20109
201119
201216
201317
201421
201519
201625
201725
201826
201915
202023
202118
202226
202322
20249
20256
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed390

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
GlaxoSmithKline9
Merck Sharp & Dohme LLC6
National Center for Complementary and Integrative Health (NCCIH)6
University of Washington6
University of Wisconsin, Madison6
Assistance Publique - Hôpitaux de Paris5
Bayer5
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.5
Leiden University Medical Center5
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Urinary Tract Infections390
Sepsis22
Pneumonia18
Pyelonephritis16
Bacterial Infections14
Bacteriuria14
Infections14
Respiratory Tract Infections14
Cystitis13
Escherichia coli Infections11

Trials

Showing 26 to 50 of 390. Each trial links to its page on Pharma Observatory.

290 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.